dantrolene has been researched along with Brain Inflammation in 2 studies
Dantrolene: Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. It is used in spasticity and other neuromuscular abnormalities. Although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.
dantrolene : The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.
Excerpt | Relevance | Reference |
---|---|---|
"LPS-infused rats had significant memory deficits in the Morris water maze, and this deficit was ameliorated by treatment with nimodipine." | 1.42 | Calcium dysregulation via L-type voltage-dependent calcium channels and ryanodine receptors underlies memory deficits and synaptic dysfunction during chronic neuroinflammation. ( Adzovic, L; Crockett, AM; D'Angelo, HM; Hopp, SC; Kaercher, RM; Royer, SE; Wenk, GL, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hopp, SC | 1 |
D'Angelo, HM | 1 |
Royer, SE | 1 |
Kaercher, RM | 1 |
Crockett, AM | 1 |
Adzovic, L | 1 |
Wenk, GL | 1 |
Linazasoro, G | 1 |
Van Blercom, N | 1 |
Castro, A | 1 |
Dapena, MD | 1 |
2 other studies available for dantrolene and Brain Inflammation
Article | Year |
---|---|
Calcium dysregulation via L-type voltage-dependent calcium channels and ryanodine receptors underlies memory deficits and synaptic dysfunction during chronic neuroinflammation.
Topics: AIDS-Related Complex; Analysis of Variance; Animals; Calcium; Calcium Channel Blockers; Calcium Chan | 2015 |
Subthalamic deep brain stimulation masking possible malignant syndrome in Parkinson disease.
Topics: Analgesics, Non-Narcotic; Anti-Infective Agents; Antiparkinson Agents; Combined Modality Therapy; Co | 2004 |